Agilent Technologies has introduced a new HPLC-Chip to address N-glycan analysis in the biopharmaceutical market.
The mAb-Glyco-Chip is designed for the analysis of N-glycans associated with monoclonal antibody molecules.
It is said to improve the productivity of biopharmaceutical analysis at least 20 times when compared to the current CE-FLD method and at least five times when compared to the current Maldi-MS method.
The HPLC-Chip/MS workflow reduces the total analysis, including on-chip enzymatic reaction, glycan separation and MS analysis, creating a productivity enhancement for biopharmaceutical analysis.
Coupled with an Agilent Accurate Mass TOF or Q-TOF mass spectrometer, the combined system allows for complete, rapid characterisation and quantitative profiling of glycan structures on recombinant antibodies.
The Agilent 1200 Series HPLC-Chip/MS system is a microfluidic chip-based technology for nanospray LC/MS.
The company offers 13 versions of HPLC-Chips, all of which are compatible across the entire portfolio of Agilent mass spectrometers for applications that include peptide quantitation, biomarker discovery, targeted phosphopeptide analysis, glycan and Monoclonal Antibody characterisation, and small-molecule DMPK studies.